The Centers for Medicare & Medicaid Services (CMS) has released information regarding coverage of new Alzheimer’s drugs for Medicare patients. For more information, click here .

CMS has announced updated Medicare coverage information for amyloid PET scans. For more information, refer to this link .

leh kem' bee Speaker icon
lecanemab Speaker icon

LEQEMBI Logo
Patient and caregiver in flower nursery
Patient and caregiver in flower nursery

Start LEQEMBI®. Change the course of AD1,2

In an 18-month study, LEQEMBI was proven to slow the progression of MCI due to AD and mild AD dementia. Learn more:

MCI=mild cognitive impairment.

Explore the latest data from the Clarity AD trial Learn how to prepare for LEQEMBI Treat and monitor for safety

The Centers for Medicare & Medicaid Services (CMS) has released information regarding coverage of new Alzheimer’s drugs for Medicare patients. For more information, click below.

Go to CMS External link icon

To learn about Eisai Patient Support for patients prescribed LEQEMBI, call 1-833-4-LEQEMBI (1-833-453-7362) or click here.

Eisai patient support logo
Learn more about LEQEMBI